Abstract: The invention relates to Guanabenz or an analogue thereof for use in the treatment and to methods of treatment of a subject that has vanishing white matter (VWM), comprising administering the compound Guanabenz or an analogue thereof to the subject in need thereof. Also provided are methods with which the success of a medical intervention in a subject with VWM can be determined. Such methods comprise quantifying the translocation of Bergmann glia into the molecular layer in the cerebellum in a suitable sample of the subject. The sample is typically a post mortem sample.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
July 12, 2022
Assignee:
Stichting VUmc
Inventors:
Margo Sientje van der Knaap, Vivi Majella Heine, Gertrude Elise Maria Abbink
Abstract: A method, system and computer readable medium for determining a strabismus angle of the eyes of an individual by: positioning the individual with his or her eyes in front of an eye tracker device and in front of a screen at a viewing distance; displaying a small image element on the screen; measuring a position and line of sight of the eyes of the individual with the eye tracker device while the individual is focussing on the small image element; forwarding the measured position and line of sight of the eyes from the eye tracker device to a computer system; and, calculating the strabismus angle between the eyes by calculating the difference in line of sight of the left and right eyes of the individual.
Abstract: Disclosed are small ncRNAs that may be used as biomarkers for classifying the health status of an individual. The disclosure also provides screening methods for identifying ncRNA biomarkers.
Type:
Application
Filed:
April 21, 2015
Publication date:
February 23, 2017
Applicants:
Stichting VUmc, Universidad de Granada, Universidad de Granada
Inventors:
Dirk Michiel Pegtel, Danijela Koppers-Lalic, Tom Wurdinger, Irene Bijnsdorp, Michael Hackenberg